Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…Abstract Number: 2436 • ACR Convergence 2025
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
Background/Purpose: Fatigue and exercise intolerance affect over 90% of patients with SLE, often persisting despite inactive disease and disrupting quality of life. Yet, the underlying…Abstract Number: 2415 • ACR Convergence 2025
Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystemic autoimmune disease that had multidimensional adverse effects on patients lives, and preferentially inflicts young women, specially…Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…Abstract Number: 2211 • ACR Convergence 2025
Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States
Background/Purpose: Despite significant advances in SLE management, women with systemic lupus erythematosus (SLE) are at risk of adverse pregnancy outcomes (APOs). We sought to determine…Abstract Number: 1942 • ACR Convergence 2025
An Agnostic Evaluation of Serum Proteins Discriminates the Severity of Ultrasound Arthritis in SLE Patients
Background/Purpose: Inflammatory arthritis occurs in up to 90% of patients and is a main cause of SLE work-related disability. SLE arthritis is difficult to evaluate…Abstract Number: 1852 • ACR Convergence 2025
Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease associated with systemic lupus erythematosus (SLE) and characterized by a prominent type I interferon…Abstract Number: 1832 • ACR Convergence 2025
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) face elevated risk of thrombotic events (TEs) due to traditional cardiovascular factors and chronic inflammation. Statins may offer…Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…Abstract Number: 1641 • ACR Convergence 2025
Association of Area Socioeconomic Deprivation with Community Mobility in a Diverse Cohort of Individuals with SLE
Background/Purpose: Community mobility (the extent to which individuals move independently throughout their community) is suboptimal among those with SLE, particularly for those who are Black,…Abstract Number: 1542 • ACR Convergence 2025
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…Abstract Number: 1523 • ACR Convergence 2025
Genetic architecture and translational insights for SLE progression from preclinical stages
Background/Purpose: Systemic lupus erythematosus (SLE), have a preclinical phase where individuals display a subset of symptoms, but do not meet the full diagnostic criteria. Identifying…Abstract Number: 1501 • ACR Convergence 2025
Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement and…Abstract Number: 1484 • ACR Convergence 2025
Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
Background/Purpose: Patients with autoimmune connective tissue disease, such as Systemic Lupus Erythematosus (SLE), are at higher risk for developing aortic valve pathology. However, the impact…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 181
- Next Page »